Daiichi wins $400M award for being deceived about Ranbaxy's problems

Indian money
Daiichi Sankyo logo

Daiichi Sankyo claimed it had been deceived when its venture into Indian generic drug manufacturing turned into a regulatory maelstrom that eventually led it to unload Ranbaxy Laboratories at a loss. Now an international arbitration court has agreed.

The Singapore Court of Arbitration has decided the Japanese drugmaker should be awarded $400 million from Malvinder Mohan Singh and Shivinder Mohan Singh, the two lead Ranbaxy investors who sold their stake in the company to Daiichi for $2.4 billion in 2008, the Economic Times reports. It paid about $4.6 billion to get controlling interest.

Daiichi filed the arbitration action against the brothers in 2013, after Ranbaxy pleaded to 7 felonies charges related to manufacturing poor quality drugs and it and Daiichi agreed to a $500 million settlement with the U.S. authorities to settle litigation.

By that point the company had had two plants banned by the FDA from shipping products to the U.S. and fallen under the provisions of a court-ordered consent decree requiring it to have outside auditors track its progress. The actions had begun after authorities were tipped off by a whistleblower that Ranbaxy, among other things, had faked test data on drug tests, showing that products met FDA standards when they did not.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

When problems persisted and the FDA banned two more Ranbaxy plants, Daiichi decided it had had enough and agreed to sell the company at a loss to Sun Pharmaceutical in an all stock deal valued at about $4 billion. Sun has pledged to fix Ranbaxy’s quality issues.

- read the Economic Times story

Related Articles: 
Daiichi Sankyo says it was burned in Ranbaxy buyout 
Daiichi Sankyo sells off Ranbaxy's problems to Sun Pharma

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.